Our trial of ondansetron as a treatment for hallucinations in Parkinson's is restarting Date 22 November 2024
Next steps for landmark stem cell study approved Date 27 October 2022 An international clinical trial looking at using stem cells to treat Parkinson’s has been granted approval to go ahead initially in Sweden.
We’re partnering with Enterin to develop a potential new treatment for Parkinson’s dementia Date 13 October 2022 We’re investing £2m in Enterin’s phase 2 clinical trial of its drug ENT-01, a potential treatment for Parkinson’s dementia.
Making progress towards a potential new GDNF trial Date 11 October 2022 Over the last 2 years, Vivifi Biotech has made progress towards a trial that aims to overcome the challenges of the last trial. Now, it’s starting work on the final phase of planning.
Ex-international rugby players have an increased risk of developing Parkinson’s Date 6 October 2022 A study following Scottish international rugby players shows they are more likely to develop neurodegenerative conditions compared to the general public.
Artificial intelligence to help identify Parkinson’s Date 23 September 2022 A project involving Parkinson’s UK, shows promise for using artificial intelligence to identify Parkinson’s in brains donated to our Brain Bank.
Hormone produced during exercise protects brain cells in mice Date 16 September 2022 Results from a US study show that a hormone called irisin has the potential to halt the progression of Parkinson’s in mice.
‘Smelling Parkinson’s’ research could make it quicker and easier to diagnose Parkinson’s Date 7 September 2022 Scientists at the University of Manchester have developed a test which could help diagnose Parkinson’s in 3 minutes using a simple skin swab.
Parkinson’s UK funding research into drug that could slow Parkinson’s progression Date 1 September 2022 The £2.9m phase 2 trial of a drug that could slow the progression of conditions like Parkinson's will be funded by the Parkinson's Virtual Biotech, our international drug discovery and development programme.
Parkinson’s UK and Parkinson’s Foundation partner up to speed up the search for new treatments Date 23 August 2022 Over the next 3 years, the US-based Parkinson’s Foundation will invest a minimum of $3m (over £2.4m) into the Parkinson’s Virtual Biotech, our international drug discovery and development programme.
Disappointing results from trials of vaccines for Parkinson’s, but hope for the future Date 12 August 2022 2 clinical trials aiming to reduce the clumps of troublesome alpha-synuclein to protect brain cells have, so far, failed to show a clear benefit for people with Parkinson’s.
